No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BPMC240719C160000
- 0.90
- 0.000.00%
15min DelayTrading May 17 10:04 ET
0.00High0.00Low
0.00Open0.90Pre Close0 Volume2 Open Interest160.00Strike Price0.00Turnover142.88%IV35.86%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.90Extrinsic Value100Contract SizeAmericanOptions Type0.0873Delta0.0065Gamma131.59Leverage Ratio-0.2479Theta0.0019Rho11.49Eff Leverage0.0269Vega
Intraday
- 5D
- Daily
News
Express News | Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Blueprint Medicines(BPMC.US) Officer Sells US$1.41 Million in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Durso-Bumpus Debra sold 12,667 shares of common stock on Jul 3, 5, 2024 at an average price of $111.26 for a total value of $1.41 million. Source: Ann
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating
Blueprint Medicines (BPMC) has an average outperform rating and price target range of $75 to $168, according to analysts polled by Capital IQ.Price: 112.41, Change: +0.71, Percent Change: +0.64
Blueprint Medicines Is Maintained at Outperform by Oppenheimer
Blueprint Medicines Is Maintained at Outperform by Oppenheimer
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
4
Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.
3
The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.
Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.
1
Read more